

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for  
Pre-Exposure Prophylaxis in HIV-Uninfected Women  
Report – April 28, 2018  
Data through : April 28, 2018  
Table 4 – Progression to Step 2 by Site**

	<b>Overall</b>	<b>Baylor</b>	<b>Blantyre</b>	<b>Botha's Hill</b>	<b>DTTC-SU</b>
Total Participants Enrolled <sup>1</sup>	132	0	0	0	0
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	89	0	0	0	0
Progressed to Step 2	83/89 (93.3%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Progression Status Pending	4/89 (4.5%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Did Not Progress to Step 2	2/89 (2.2%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product	1/89 (1.1%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Terminated from the study	1/89 (1.1%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/89 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for  
Pre-Exposure Prophylaxis in HIV-Uninfected Women  
Report – April 28, 2018  
Data through : April 28, 2018  
Table 4 – Progression to Step 2 by Site**

	<b>Emavundleni</b>	<b>Gaborone</b>	<b>Isipingo</b>	<b>Kisumu</b>	<b>Lilongwe</b>
Total Participants Enrolled <sup>1</sup>	0	8	0	0	0
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	0	6	0	0	0
Progressed to Step 2	0/0 (-%)	5/6 (83.3%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Progression Status Pending	0/0 (-%)	0/6 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Did Not Progress to Step 2	0/0 (-%)	1/6 (16.7%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product	0/0 (-%)	1/6 (16.7%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Terminated from the study	0/0 (-%)	0/6 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (-%)	0/6 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Report – April 28, 2018**  
**Data through : April 28, 2018**  
**Table 4 – Progression to Step 2 by Site**

	<b>MU-JHU</b>	<b>Parirenyatwa</b>	<b>Seke South</b>	<b>Soweto</b>	<b>Spilhaus</b>
Total Participants Enrolled <sup>1</sup>	0	20	0	33	0
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	0	8	0	28	0
Progressed to Step 2	0/0 (-%)	8/8 (100.0%)	0/0 (-%)	27/28 (96.4%)	0/0 (-%)
Progression Status Pending	0/0 (-%)	0/8 (0.0%)	0/0 (-%)	0/28 (0.0%)	0/0 (-%)
Did Not Progress to Step 2	0/0 (-%)	0/8 (0.0%)	0/0 (-%)	1/28 (3.6%)	0/0 (-%)
Permanently discontinued from the study product	0/0 (-%)	0/8 (0.0%)	0/0 (-%)	0/28 (0.0%)	0/0 (-%)
Terminated from the study	0/0 (-%)	0/8 (0.0%)	0/0 (-%)	1/28 (3.6%)	0/0 (-%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (-%)	0/8 (0.0%)	0/0 (-%)	0/28 (0.0%)	0/0 (-%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for  
Pre-Exposure Prophylaxis in HIV-Uninfected Women  
Report – April 28, 2018  
Data through : April 28, 2018  
Table 4 – Progression to Step 2 by Site**

	St.Mary's Clinic	Swaziland	UVRI-IAVI	Verulam	Ward 21
Total Participants Enrolled <sup>1</sup>	24	0	0	0	32
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	7	0	0	0	27
Progressed to Step 2	5/7 (71.4%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	26/27 (96.3%)
Progression Status Pending	2/7 (28.6%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	1/27 (3.7%)
Did Not Progress to Step 2	0/7 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/27 (0.0%)
Permanently discontinued from the study product	0/7 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/27 (0.0%)
Terminated from the study	0/7 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/27 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/7 (0.0%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/27 (0.0%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Report – April 28, 2018**  
**Data through : April 28, 2018**  
**Table 4 – Progression to Step 2 by Site**

	<b>Zengeza</b>
Total Participants Enrolled <sup>1</sup>	15
Participants who have been enrolled for 6 weeks or received injection <sup>2</sup>	13
Progressed to Step 2	12/13 (92.3%)
Progression Status Pending	1/13 (7.7%)
Did Not Progress to Step 2	0/13 (0.0%)
Permanently discontinued from the study product	0/13 (0.0%)
Terminated from the study	0/13 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/13 (0.0%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Participants who did not progress to Step 2 due to HIV infection are not included.